EVMN

7.0402.76%
JP

Jeegar Patel

Chief Scientific Officer

Dr. Jeegar Patel, Ph.D. is the Chief Scientific Officer of Evommune, Inc. from October, 2022. He joined Evommune in October, 2022 with significant scientific and biotech industry experience, with a focus on drug discovery, toxicology and the clinical translation of therapeutics from target selection to registrational filing. He was Senior Vice President of Research & Non-Clinical Development at Kadmon Holdings, Inc., a Sanofi Company, where he held positions of increasing responsibility and led the research and development organization with a therapeutic focus in fibrosis, immunology and immuno-oncology. He has directly contributed to IND and NDA filings across multiple therapeutic areas, including the development and approval of Rezurock® (FDA Approved July 2021) which led to Sanofi's acquisition of Kadmon in late 2021, with Dr. Patel leading Kadmon's R&D activity integration into Sanofi. Prior to joining Kadmon, he was a Nonclinical Development Project Leader at ImClone Systems (Acquired by Eli Lilly in 2008) and led nonclinical development activities supporting the approval of Cyramza® (aVEGFR2 Mab), Portrazza® (aEGFR Mab), and Lartruvo® (aPDGFb Mab). He began his career as a nonclinical development project toxicologist at Abbott Laboratories and Aventis. He received his Bachelor of Science (B.S.) degree in Pharmacology and Toxicology from the University of the Sciences in Philadelphia and his Doctorate in Pharmacology and Physiology (Ph.D.) from Drexel University, College of Medicine.

Positions